Forsta AP Fonden Sells 2,480 Shares of IDEXX Laboratories, Inc. $IDXX

Forsta AP Fonden lessened its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 6.5% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 35,920 shares of the company’s stock after selling 2,480 shares during the quarter. Forsta AP Fonden’s holdings in IDEXX Laboratories were worth $24,301,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Virtus Advisers LLC bought a new stake in IDEXX Laboratories in the third quarter valued at about $26,000. Park Place Capital Corp bought a new stake in IDEXX Laboratories in the fourth quarter valued at about $29,000. Mowery & Schoenfeld Wealth Management LLC increased its holdings in IDEXX Laboratories by 58.8% in the fourth quarter. Mowery & Schoenfeld Wealth Management LLC now owns 54 shares of the company’s stock valued at $37,000 after purchasing an additional 20 shares during the last quarter. Greykasell Wealth Strategies Inc. bought a new stake in shares of IDEXX Laboratories in the third quarter worth about $35,000. Finally, WealthCollab LLC bought a new stake in shares of IDEXX Laboratories in the second quarter worth about $30,000. Institutional investors own 87.84% of the company’s stock.

Insider Buying and Selling

In related news, EVP Nimrata Hunt sold 1,758 shares of the stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $634.57, for a total transaction of $1,115,574.06. Following the completion of the transaction, the executive vice president directly owned 18,141 shares of the company’s stock, valued at approximately $11,511,734.37. This represents a 8.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.79% of the company’s stock.

IDEXX Laboratories Stock Down 0.8%

IDXX stock opened at $563.53 on Friday. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.12 and a quick ratio of 0.82. The stock has a market capitalization of $44.45 billion, a P/E ratio of 41.50, a P/E/G ratio of 3.27 and a beta of 1.58. The business has a 50-day moving average of $564.58 and a 200-day moving average of $637.19. IDEXX Laboratories, Inc. has a fifty-two week low of $504.56 and a fifty-two week high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, beating the consensus estimate of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The firm had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.12 billion. During the same period in the prior year, the firm posted $2.91 earnings per share. The business’s quarterly revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. UBS Group lowered their price target on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a report on Tuesday, April 28th. Barclays lowered their price target on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating for the company in a report on Thursday, February 5th. Weiss Ratings downgraded IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, May 11th. Piper Sandler lowered their price target on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a report on Monday, February 9th. Finally, Citigroup assumed coverage on IDEXX Laboratories in a report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price target for the company. Seven analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, IDEXX Laboratories has an average rating of “Moderate Buy” and an average target price of $751.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.